Genentech Inc patents expiration
1. Cotellic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(6 years from now) | |
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(12 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(12 years from now) | |
| US11254649 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Jun, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(3 years from now) | |
| US11597699 | GENENTECH INC | MEK inhibitors and methods of their use |
Oct, 2026
(3 years from now) | |
|
US8362002 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(3 years from now) | |
|
US7803839 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(6 years from now) | |
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(10 years from now) | |
|
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(11 years from now) | |
|
US10478400 (Pediatric) | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Dec, 2036
(13 years from now) | |
|
US11254649 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Dec, 2036
(13 years from now) | |
|
US10590102 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Dec, 2036
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Oct 28, 2025 |
| M (M) | Jul 28, 2025 |
| Orphan Drug Exclusivity (ODE) | Oct 28, 2029 |
| Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma; As a single agent for the treatment of adult patients with histiocytic neoplasms
Dosage: TABLET;ORAL
COTELLIC family patents
2. Esbriet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561217 | GENENTECH INC | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(1 year, 7 months ago) | |
| US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
| US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
| US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
| US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
| US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
| US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
| US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(4 years from now) | |
| US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
| US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
| US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
| US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
| US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
| US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
| US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
| US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(9 years from now) | |
| US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(13 years from now) | |
Drugs and Companies using PIRFENIDONE ingredient
Market Authorisation Date: 11 January, 2017
Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-1...
Dosage: TABLET;ORAL
ESBRIET family patents
3. Evrysdi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(9 years from now) | |
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 27, 2029 |
| New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
| New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 2024-08-07
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
EVRYSDI family patents
4. Gavreto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 4, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 4, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 2024-09-04
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...
Dosage: CAPSULE;ORAL
GAVRETO family patents
5. Rozlytrek patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(4 years from now) | |
| US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(5 years from now) | |
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(9 years from now) | |
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(4 years from now) | |
| US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(4 years from now) | |
| US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(4 years from now) | |
| US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(4 years from now) | |
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(9 years from now) | |
| US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(11 years from now) | |
| US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(11 years from now) | |
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(13 years from now) | |
| US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(14 years from now) | |
| US11253515 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 15, 2024 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 2023-08-16
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrop...
Dosage: CAPSULE;ORAL
ROZLYTREK family patents
6. Xofluza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(7 years from now) | |
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(12 years from now) | |
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(6 years from now) | |
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(7 years from now) | |
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(12 years from now) | |
| US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(13 years from now) | |
| US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 2022-10-24
Market Authorisation Date: 23 November, 2020
Treatment: Method for post-exposure prophylaxis of influenza; Method for treating influenza
Dosage: FOR SUSPENSION;ORAL
XOFLUZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic